Treatment-emergent bleeding events occurring in >1 subject in any treatment group in pooled phase II/III clinical trial program
| Intravenous meloxicam | ||||
| Placebo n=517 | 5–15 mg n=327 | 30 mg n=910 | 60 mg n=189 | |
| Subjects with ≥1 bleeding event, n (%) | 11 (2.1) | 30 (9.2) | 33 (3.6) | 19 (10.1) |
| Anemia | 6 (1.2) | 26 (8.0) | 19 (2.1) | 18 (9.5) |
| Anemia postoperative | 1 (0.2) | 0 | 4 (0.4) | 0 |
| Ecchymosis | 0 | 0 | 3 (0.3) | 0 |
| Postprocedural hematoma | 0 | 2 (0.6) | 0 | 1 (0.5) |
| Wound hematoma | 0 | 0 | 3 (0.3) | 0 |